Variable | Treatment group (n = 177) | Control group (n = 180) | P value |
---|---|---|---|
Migraine attacks | |||
 4 W | 2.66 ± 1.40 | 2.66 ± 1.20 | 0.864 |
 8 W | 2.04 ± 1.30 | 1.93 ± 1.19 | 0.153 |
 12 W | 1.57 ± 1.46 | 1.42 ± 1.12 | 0.460 |
 Follow-up period | 1.37 ± 1.30 | 1.55 ± 1.30 | 0.398 |
Migraine days | |||
 4w | 2.98 ± 1.74 | 2.91 ± 1.41 | 0.994 |
 8w | 2.25 ± 1.72 | 2.13 ± 1.42 | 0.588 |
 12 w | 1.73 ± 1.78 | 1.58 ± 1.34 | 0.093 |
 Follow-up period | 1.46 ± 1.55 | 1.68 ± 1.50 | 0.001* |
VAS scores | |||
 4w | 4.94 ± 1.26 | 4.79 ± 1.14 | 0.990 |
 8w | 4.34 ± 1.31 | 4.22 ± 1.23 | 0.404 |
 12 w | 3.58 ± 1.05 | 3.26 ± 1.47 | 0.141 |
 Follow-up period | 3.87 ± 1.25 | 3.85 ± 1.41 | 0.852 |
Total Duration(h) | |||
 4w | 19.70 ± 19.69 | 19.18 ± 19.24 | 0.009* |
 8w | 14.68 ± 21.83 | 12.41 ± 14.41 | 0.753 |
 12 w | 11.71 ± 24.83 | 8.69 ± 12.89 | 0.526 |
 Follow-up period | 7.55 ± 13.76 | 7.31 ± 11.74 | 0.140 |
Analgesic consumption (times) | |||
 4w | 0.96 ± 1.30 | 1.01 ± 1.59 | 0.229 |
 8w | 0.86 ± 1.65 | 0.76 ± 1.42 | 0.862 |
 12w | 0.70 ± 1.52 | 0.51 ± 1.07 | 0.360 |
 Follow-up period | 0.51 ± 1.37 | 0.41 ± 1.29 | 0.652 |